Singapore, Aug. 7 -- Northwest Biotherapeutics, a US-based biotechnology company developing DCVax(R) personalised immune therapies for solid tumour cancers, has entered into a non-binding Memorandum of Understanding (MoU) with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) for a collaboration to bring the company's DCVax(R)-L products and technology to Saudi Arabia. SPIMACO is one of the largest pharmaceutical companies in Saudi Arabia and a leader in 21 markets across the Middle East North Africa (MENA) region.

The MoU establishes a general framework for discussions for the potential collaboration regarding the approval, commercialisation, supply and technology transfer of the company's DCVax(R)-L product fo...